Filtered By:
Drug: Estradiol
Therapy: Hormonal Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 20 results found since Jan 2013.

Stroke Characteristics, Risk Factors, and Outcomes in Transgender Adults: A Case Series
Conclusions: Understanding unique vulnerabilities of the transgender community for cerebrovascular events is essential to provide culturally appropriate counseling for harm reduction.
Source: The Neurologist - March 1, 2019 Category: Neurology Tags: Case Report/Case Series Source Type: research

Risk of stroke in healthy postmenopausal women during and after hormone therapy: a meta-analysis
ConclusionsThese findings suggest that HT may increase the risk of stroke during, but not after, HT in healthy postmenopausal women.
Source: Menopause - October 30, 2014 Category: OBGYN Tags: Original Articles Source Type: research

Vaginal estradiol use and the risk for cardiovascular mortality
STUDY QUESTION Does the use of post-menopausal vaginal estradiol (VE) affect the mortality risk for coronary heart disease (CHD) and stroke. SUMMARY ANSWER The use of VE reduces the risk for cardiovascular mortality. WHAT IS KNOWN ALREADY A growing number of women use VE for post-menopausal genitourinary symptoms. Although this therapy is intended to have only local effects, estrogen is absorbed into the blood circulation and thus VE use may also have systemic effects. STUDY DESIGN, SIZE, DURATION We studied a nationwide cohort in Finland 1994–2009 during which post-menopausal women (n = 195 756) initiated the use...
Source: Human Reproduction - March 15, 2016 Category: Reproduction Medicine Authors: Mikkola, T. S., Tuomikoski, P., Lyytinen, H., Korhonen, P., Hoti, F., Vattulainen, P., Gissler, M., Ylikorkala, O. Tags: Puberty, Aging and HRT Source Type: research

Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality
Conclusions: In absolute terms, the risk reductions mean 19 fewer CHD deaths and 7 fewer stroke deaths per 1,000 women using any HT for at least 10 years.
Source: Menopause - August 28, 2015 Category: OBGYN Tags: Original Articles Source Type: research

Managing menopause.
Authors: Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Johnston S, Rowe T, Sodhi N, Wilks P, Wolfman W, Menopause and Osteoporosis Working Group, Fortier M, Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Graves L, Guthrie B, Khan A, Johnston S, Rowe T, Sodhi N, Wilks P, Wolfman W Abstract OBJECTIVE: To provide updated guidelines for health care providers on the management of menopause in asymptomatic healthy women as well as in women presenting with vasomotor or urogenital symptoms and on considerations related to cardiovascular disease, breast cancer, urogynaecology, and sexuality. OUTCOMES: Lifestyle...
Source: Journal of Obstetrics and Gynaecology Canada : JOGC - December 2, 2014 Category: OBGYN Tags: J Obstet Gynaecol Can Source Type: research

Can HRT in early menopause cut heart disease risk?
ConclusionThis double-blind RCT found that women taking HRT less than six years after the menopause had slower artery wall thickening than those taking a placebo. This represented the main measure of atherosclerosis progression tested; other measures showed no difference, so the results were not as conclusive as they could have been. Women taking HRT 10 or more years after menopause also showed no difference in atherosclerosis progression compared with a placebo, further complicating the picture.An important limitation of this study is the lack of a patient relevant endpoint, such as cardiovascular events or mortality. Pre...
Source: NHS News Feed - April 1, 2016 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news

Sex Differences in Sex Hormone Profiles and Prediction of Consciousness Recovery After Severe Traumatic Brain Injury
Conclusion: These findings indicate that TBI differentially affects the levels of sex-steroid hormones in men and women patients. Plasma levels of testosterone could be a good candidate blood marker to predict recovery from unconsciousness after sTBI for male patients. Introduction Traumatic brain injury (TBI) is a major cause of death and disability worldwide and is increasing in incidence (1). Patients with acute severe TBI (sTBI) often develop severe disorders of consciousness, i.e., coma, minimally conscious state or vegetative state. Although many patients may regain consciousness during the 1-month post-TBI p...
Source: Frontiers in Endocrinology - April 25, 2019 Category: Endocrinology Source Type: research

SIRT1-dependent AMPK pathway in the protection of estrogen against ischemic brain injury.
CONCLUSION: Our data support that estrogen protects against ischemic stroke through preventing neuron death via the SIRT1-dependent AMPK pathway. PMID: 28256111 [PubMed - as supplied by publisher]
Source: CNS Neuroscience and Therapeutics - March 1, 2017 Category: Neuroscience Authors: Guo JM, Shu H, Wang L, Xu JJ, Niu XC, Zhang L Tags: CNS Neurosci Ther Source Type: research

In assessing risk of hormone therapy for menopause, dose — not form — matters
FINDINGSWhen it comes to assessing the risk of estrogen therapy for menopause, how the therapy is delivered — taking a pill versus wearing a patch on one’s skin — doesn’t affect risk or benefit, researchers at UCLA and elsewhere have found. But with the commonly used conjugated equine estrogen, plus progestogen, the dosage does. Higher doses, especially over time, are associated with greater risk of problems, including heart disease and some types of cancer, especially among obese women.BACKGROUNDThe Women ’s Health Initiative established the potential of estrogen therapy to increase or decrease the risk of strok...
Source: UCLA Newsroom: Health Sciences - July 27, 2017 Category: Universities & Medical Training Source Type: news

17-beta estradiol inhibits oxidative stress-induced accumulation of AIF into nucleolus and PARP1-dependent cell death via estrogen receptor alpha.
Abstract Oxidative stress-induced DNA damage results in over-activation of poly(ADP-ribose) polymerase 1 (PARP1), leading to parthanatos, a newly discovered cell elimination pathway. Inhibition of PARP1-dependent cell death has shown to improve the outcome of diseases, including stroke, heart ischemia, and neurodegenerative diseases. In the present study we aimed to detect whether estrogen plays a protective role in inhibiting parthanatos. We utilized human mammary adenocarcinoma cells (MCF7) that abundantly express the estrogen receptor alpha and beta (ERα and ERβ). Parthanatos was induced by challenging the ce...
Source: Toxicology Letters - September 30, 2014 Category: Toxicology Authors: Batnasan E, Wang R, Wen J, Ke Y, Li X, Bohio AA, Zeng X, Huo H, Han L, Boldogh I, Ba X Tags: Toxicol Lett Source Type: research

From the 90׳s to now: A brief historical perspective on more than two decades of estrogen neuroprotection.
This article is part of a Special Issue entitled SI:50th Anniversary Issue. PMID: 26740397 [PubMed - as supplied by publisher]
Source: Brain Research - December 29, 2015 Category: Neurology Authors: Engler-Chiurazzi EB, Singh M, Simpkins JW Tags: Brain Res Source Type: research

Reprint of: From the 90׳s to now: A brief historical perspective on more than two decades of estrogen neuroprotection.
This article is part of a Special Issue entitled SI:50th Anniversary Issue. PMID: 27317847 [PubMed - as supplied by publisher]
Source: Brain Research - June 14, 2016 Category: Neurology Authors: Engler-Chiurazzi EB, Singh M, Simpkins JW Tags: Brain Res Source Type: research

Bioidentical hormones for women with vasomotor symptoms.
CONCLUSIONS: There was low to moderate quality evidence that BHT in various forms and doses is more effective than placebo for treating moderate to severe menopausal hot flushes. There was low to moderate quality evidence of higher rates of adverse effects such as headache, vaginal bleeding, breast tenderness and skin reactions in the BHT group. There was some evidence to suggest that higher doses of BHT are associated with greater effectiveness but also with higher risk of adverse effects. Although all the included studies used unopposed estrogen, it is recommended best practice to use progestogen therapy in women with a ...
Source: Cochrane Database of Systematic Reviews - July 31, 2016 Category: Journals (General) Authors: Gaudard AM, Silva de Souza S, Puga ME, Marjoribanks J, da Silva EM, Torloni MR Tags: Cochrane Database Syst Rev Source Type: research

Custom-compounded bioidentical hormone therapy: why so popular despite potential harm? The case against routine use.
Abstract Wide rejection of conventional hormone therapy (HT) after the initial publication of the Women's Health Initiative (WHI) led to unjustified use of custom-compounded bioidentical hormones. In the USA, it became an unregulated drug manufacturer industry in disguise, without proper control and making false claims and misleading advertisements. Manufacturing quality is not ensured. Unspecific harm from compounding has occurred on a large scale, such as deaths from infected products and end-stage renal failure plus carcinoma due to confusion between different Chinese herbs. Oral estrogens increase venous throm...
Source: Climacteric - May 18, 2017 Category: Geriatrics Authors: L'Hermite M Tags: Climacteric Source Type: research

Estrogen-based hormone therapy in women with primary ovarian insufficiency: a systematic review
ConclusionsEvidence supporting bone and cardiovascular benefits of HT in women with POI is limited by high risk of bias, reliance on surrogate outcomes, and heterogeneity of trials regarding the formulation, dose, route of administration, and regimen of HT. Further research addressing patient important outcomes such as fractures, stroke, and cardiovascular mortality are crucial to optimize benefits of this therapy.
Source: Endocrine - October 16, 2017 Category: Endocrinology Source Type: research